ISRCTN04058380 https://doi.org/10.1186/ISRCTN04058380

The British rheumatoid outcome study group (BROSG) trial of symptomatic versus aggressive therapy in established rheumatoid arthritis

Submission date
25/04/2003

Recruitment status
No longer recruiting

Registration date
25/04/2003

Overall study status
Completed

Last Edited
24/08/2009

Condition category
Musculoskeletal Diseases

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[X] Results
[ ] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Deborah Symmons

Contact details
ARC Epidemiology Research Unit
University of Manchester
Oxford Road
Stopford Building
Manchester
United Kingdom
M13 9PT
+44 (0)161 275 5044
deborah@fs1.ser.man.ac.uk

Additional identifiers

Protocol serial number
HTA 94/45/02

Study information

Scientific Title

Acronym
BROSG

Study objectives
This multi-centre observer-blinded controlled trial will compare the outcome, in terms of disability, of two groups of 240 RA patients with 5-20 years disease duration. Group 1 will be managed predominantly in primary care with the goal of controlling joint pain and stiffness. Group 2 will be predominantly in the rheumatology clinic with the goal of controlling symptoms and suppressing clinical laboratory evidence of inflammation. Only Group 2 will be eligible to receive cytotoxic drugs and parenteral steroids. Both groups will attend an annual review clinic to be screened for the complications of RA. Algorithms will guide physicians in their choice of drugs. The study will include assessment of direct and indirect costs. The multi-professional project team will include clinicians, an epidemiologist, statistician, computer scientist and a health economist.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Multi-centre observer-blinded controlled trial

Primary study design
Interventional

Study type(s)
Screening

Health condition(s) or problem(s) studied
Rheumatoid arthritis

Interventions
Group 1 will be managed predominantly in primary care with the goal of controlling joint pain and stiffness. Group 2 will be predominantly in the rheumatology clinic with the goal of controlling symptoms and suppressing clinical laboratory evidence of inflammation. Only Group 2 will be eligible to receive cytotoxic drugs and parenteral steroids.

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s))
Not provided at time of registration

Completion date
31/07/2002

Eligibility

Key inclusion criteria
Patients with rheumatoid arthritis of 5-20 years duration

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/05/1997

Date of final enrolment
31/07/2002

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
ARC Epidemiology Research Unit
Manchester
United Kingdom
M13 9PT

Sponsor information

Organisation
Department of Health (UK)

ROR
https://ror.org/03sbpja79

Funder(s)

Funder type
Government

Funder Name
NIHR Health Technology Assessment Programme - HTA (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2005		Yes	No